Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results

被引：23

作者：

Gallant, Joel E. ^{[1
]}

Koenig, Ellen ^{[2
]}

Andrade-Villanueva, Jaime F. ^{[3
]}

Chetchotisakd, Ploenchan ^{[4
]}

DeJesus, Edwin ^{[5
]}

Antunes, Francisco ^{[6
]}

Arasteh, Keikawus ^{[7
]}

Rizzardini, Giuliano ^{[8
]}

Fehr, Jan ^{[9
]}

Liu, Hui C. ^{[10
]}

Abram, Michael E. ^{[10
]}

Cao, Huyen ^{[10
]}

Szwarcberg, Javier ^{[10
]}

机构：

[1] Southwest CARE Ctr, Santa Fe, NM USA

[2] Inst Dominicano Estudios Virolog, Santo Domingo, Dominican Rep

[3] Hosp Civil Guadalajara, HIV Unit, Guadalajara, Jalisco, Mexico

[4] Khonkaen Univ, Dept Med, Khon Kaen, Thailand

[5] Orlando Immunol Ctr, Orlando, FL USA

[6] Fac Med Lisbon, Inst Saude Ambiental, Lisbon, Portugal

[7] Vivantes Auguste Viktoria Klinikum, EPIMED, Berlin, Germany

[8] Luigi Sacco Hosp, Dept Infect Dis, Milan, Italy

[9] Univ Zurich, Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland

[10] Gilead Sci Inc, Foster City, CA 94404 USA

来源：

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2015年 / 69卷 / 03期

关键词：

Cobicistat; pharmacoenhancer; HIV; Antiretroviral; clinical trial; INITIAL TREATMENT; TREATMENT-NAIVE; DOUBLE-BLIND; LOPINAVIR/RITONAVIR; PHARMACOKINETICS; INFECTION; GS-9350; REGIMEN;

D O I：

10.1097/QAI.0000000000000598

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background:Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity.Methods:International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144.Results:At Week 144, virologic suppression was achieved in 72% (COBI) and 74% (RTV) of patients. Adverse events leading to study drug discontinuation occurred in 11% of patients in each group. Median changes in serum creatinine (mg/dL) were +0.13 (COBI) and +0.07 (RTV) and were unchanged from week 48.Conclusions:Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor atazanavir.

引用

页码：338 / 340

页数：3

共 50 条

[21] Darunavir/emtricitabine/ritonavir/tenofovir disoproxil fumarateGuillain-Barré syndrome (first report with darunavir and emtricitabine/tenofovir disoproxil fumarate): case report
Reactions Weekly, 2014, 1514 (1) : 20 - 20
[22] Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat/fluticasone propionate interactionAdrenal suppression: case report
Reactions Weekly, 2015, 1553 (1) : 127 - 127
[23] Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection
Nozza, Silvia
Poli, Andrea
Ripa, Marco
Galli, Laura
Chiappetta, Stefania
Spagnuolo, Vincenzo
Rovelli, Cristina
Lazzarin, Adriano
Castagna, Antonella
Tambussi, Giuseppe
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (02) : 632 - 633
[24] Week 96 efficacy and safety data: Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF in treatment-naive HIV-1-infected patients
Orkin, C.
Rockstroh, J.
DeJesus, E.
Henry, K.
Molina, J.
Gathe, J.
Wei, X.
Fordyce, M.
Rhee, M.
Smith, A.
Szwarcberg, J.
HIV MEDICINE, 2013, 14 : 56 - 56
[25] Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
DeJesus, Edwin
Rockstroh, Juergen K.
Henry, Keith
Molina, Jean-Michel
Gathe, Joseph
Ramanathan, Srinivasan
Wei, Xuelian
Yale, Kitty
Szwarcberg, Javier
White, Kirsten
Cheng, Andrew K.
Kearney, Brian P.
LANCET, 2012, 379 (9835): : 2429 - 2438
[26] Atazanavir/ritonavir/lopinavir/tenofovir disoproxil fumarate interactionDecreased GFR and proteinuria: 3 case reports
Reactions Weekly, 2018, 1685 (1) : 32 - 32
[27] Common adverse drug reactions of elvitegravir, cobicistat, and emtricitabine co-formulated with tenofovir alafenamide or tenofovir disoproxil fumarate
Segal-Maurer, S.
Henry, K.
Benson, P.
Brinson, C.
Crofoot, G.
Guo, S.
Esser, P.
Nguyen-Cleary, T.
Das, M.
McCallister, S.
ANTIVIRAL THERAPY, 2016, 21 : A51 - A51
[28] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet for HIV-1 Infection Treatment
Olin, Jacqueline L.
Spooner, Linda M.
Klibanov, Olga M.
ANNALS OF PHARMACOTHERAPY, 2012, 46 (12) : 1671 - 1677
[29] Comment on: Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection
Ambrosioni, Juan
Mosquera, Maria M.
Miro, Jose M.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (05) : 1548 - 1549
[30] Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients
Gazzard, BG
EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (06) : 793 - 802

← 1 2 3 4 5 →